<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312674</article-id>
      <article-id pub-id-type="pmc">4540508</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153462</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>HTLV-1-associated infective dermatitis and probable HTLV-1- associated
myelopathy in an adolescent female<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Steglich</surname>
            <given-names>Raquel Bisacotti</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tonoli</surname>
            <given-names>Renata Elise</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Souza</surname>
            <given-names>Paulo Ricardo Martins</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>Giselle Martins</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Riesgo</surname>
            <given-names>Rudimar dos Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Universidade da Regi&#xE3;o de Joinville (UNIVILLE) - Joinville
(SC), Brazil.</aff>
      <aff id="aff02"><label>2</label>Santa Casa de Miseric&#xF3;rdia de Porto Alegre - Porto Alegre
(RS), Brazil.</aff>
      <aff id="aff03"><label>3</label>Pontif&#xED;cia Universidade Cat&#xF3;lica do Rio Grande do Sul
(PUCRS) - Porto Alegre (RS), Brazil.</aff>
      <aff id="aff04"><label>4</label>Universidade Federal do Rio Grande do Sul (UFRGS) - Porto
Alegre (RS), Brazil.</aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Renata Elise Tonoli, Rua Prof. Annes Dias, 285 -
Centro, 90020-090 - Porto Alegre - RS, Brazil. E-mail:
<email>retonoli@hotmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>55</fpage>
      <lpage>58</lpage>
      <history>
        <date date-type="received">
          <day>18</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>6</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Human T cell lymphotropic virus type 1 (HTLV-1)-associated infective dermatitis (ID)
is a chronic, severe and recurrent eczema occurring during childhood in patients
vertically infected with HTLV-1. HTLV-1-associated myelopathy/tropical spastic
paraparesia (HAM/ TSP) is slow and progressive. We report the case of an adolescent
female from a non-endemic area for HTLV-1 who presents ID and, most likely,
associated HAM/TSP.</p>
      </abstract>
      <kwd-group>
        <kwd>Dermatitis</kwd>
        <kwd>Demyelinating diseases</kwd>
        <kwd>Human T-lymphotropic virus 1</kwd>
        <kwd>Paraparesis, tropical spastic</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The HTLV-1 is a retrovirus of the family Retroviridae, genus Deltaretrovirus, which
integrates into T-helper (CD4+) lymphocytes, leading to a lifelong cell infection. It is
estimated that 10 to 20 million individuals are infected with HTLV-1 worldwide. Regions
of HTLV-1 endemicity, with proportionately higher rates of infection, are clustered in
Japan, the Caribbean, South and Central America, equatorial Africa, and Iran. No
population study to date has reported on the real prevalence of HTLV-1 carriers in
Brazil. However, Brazil is considered to have the largest absolute number of individuals
infected with HTLV: about 2.5 million carriers. Salvador is the area with the highest
prevalence rate (1.76%).<sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>HTLV-1 is transmitted primarily through sexual contact. The second major mode of
transmission is vertical transmission, followed by blood transfusions and use of
contaminated material. In the case of intravenous transmissions, seroconversion occurs
in 40-60% of recipients. Breastfeeding has a more important role than intrauterine or
perinatal transmission. There is a positive correlation between the duration of
breastfeeding and proviral load in breast milk.<sup><xref rid="r02" ref-type="bibr">2</xref>-<xref rid="r09" ref-type="bibr">9</xref></sup></p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>16-year-old female patient, student, hospitalized, born and living in Porto Alegre/RS.
Unknown perinatal history. The patient has had erythematous, scaly rash on the cephalic
segment, trunk and large folds since early childhood. In adolescence, she developed
erythema and yellowish, adherent and fetid crusts on the scalp, eyelid, ear and
retroauricular eczema, and micropapular rash on the trunk (<xref ref-type="fig" rid="f01">Figures 1</xref>, <xref ref-type="fig" rid="f02">2</xref> and <xref ref-type="fig" rid="f03">3</xref>). She had painless cervical and axillary
lymphadenopathy.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Yellowish, adherent crusts on the scalp</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0055-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Retroauricular eczema and erythematous scaly rash on the scalp</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0055-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Micropapular rash on the trunk</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0055-g03"/>
      </fig>
      <p>3 years earlier, she presented with progressive gait alteration and one year earlier,
with urinary urge incontinence and constipation. Neurological examination revealed
pyramidal syndrome, in which the lower limbs exhibit distal atrophy, spasticity,
reduction in force, hyperreflexia, Babinsky sign, bilateral clonus and
parapareto-spastic gait.</p>
      <p>Positive serology for HTLV-1 was detected by Western blot. Histopathology of the scalp
revealed: moderate psoriasiform acanthosis, parakeratosis and mild spongiosis.
Lymphocytic infiltrate with a predominance of CD8 + lymphocytes in the dermis (<xref ref-type="fig" rid="f04">Figure 4</xref>). The urodynamics findings are compatible
with neurogenic bladder. MRI showed atrophy of the thoracic spinal cord.</p>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Histopathology of the scalp: moderate psoriasiform acanthosis, parakeratosis and
mild spongiosis. Immunohistochemistry: lymphocytic infi ltrate with a predominance
of CD8 + lymphocytes in the dermis</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0055-g04"/>
      </fig>
      <p>The patient showed cutaneous improvement when treated with sulfamethoxazole-trimethoprim
and rapid recurrence of symptoms with discontinuation of treatment.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Over 90% of individuals infected with HTLV-1 remain asymptomatic. Of these infected
individuals, 3% develop adult T cell leukemia/lymphoma after a latency period of 20
years. Another 3% develop HTLV-I-associated myelopathy/tropical spastic paraparesis
(HAM/TSP), which is a severe and disabling disease, characterized by a slow and
progressive demyelination of the pyramidal tracts.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> Its pathogenesis may
involve an autoimmune reaction triggered by viruses or destructive cytotoxic effect of
infected T cells. Gait disturbances, weakness, stiffness of the lower limbs and
compromised dynamic balance are the main presenting symptoms of myelopathy. In 1986, new
diagnostic criteria for HAM / TSP were established (<xref ref-type="table" rid="t01">Chart 1</xref>). <sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r07" ref-type="bibr">7</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>CHART 1</label>
        <caption>
          <p>Diagnostic Criteria of Osame et al HAM/ TSP (1986)</p>
        </caption>
        <table frame="box" rules="groups">
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">1.</td>
              <td align="left" rowspan="1" colspan="1">Definitive HTLV-1 Associated Myelopathy (HAM)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">1.1.</td>
              <td align="left" rowspan="1" colspan="1">Slowly progressive paraparesis, caused by symmetric
myelopathy, predominantly involving pyramidal pathways.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">1.2.</td>
              <td align="left" rowspan="1" colspan="1">Anti-HTLV-1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">1.3.</td>
              <td align="left" rowspan="1" colspan="1">Anti-HTLV-1 antibodies present in liquor</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2.</td>
              <td align="left" rowspan="1" colspan="1">Probable HAM</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2.1</td>
              <td align="left" rowspan="1" colspan="1">Paraparesis similar to the described in item 1.1 in patient
with anti-HTLV-1 antibodies present in serum or liquor (but not in both)
or</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2.2</td>
              <td align="left" rowspan="1" colspan="1">c inconsistent with the definition of item 1.1 in patient with
anti-HTLV-1 antibodies present in serum and in liquor simultaneously</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN01">
            <p>Source: Bittencourt AL, 2001<sup><xref rid="r01" ref-type="bibr">1</xref></sup>
e Santos FLN, 2005.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>Some vertically infected children may develop infective dermatitis (ID). The onset of
symptoms usually starts at 18 months of age and resolves during adolescence. The first
cases with onset in adulthood have been recently described.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r08" ref-type="bibr">8</xref></sup></p>
      <p>At the time of the study by Lee et al, 298 cases of IDH had been confirmed. Most cases
occur in Jamaica and Brazil. In the latter, the area with the highest incidence is
Salvador/BA. One study showed that, in Jamaica, children vertically infected by HTLV-1
have a 2% chance of developing ID at the age of four.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>ID is characterized by a severe, recurrent, infected eczematous and exudative dermatitis
with scaling and crusting primarily affecting the scalp, forehead, paranasal area, neck,
retroauricular areas, armpits, and groins.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r05" ref-type="bibr">5</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup> Chronic watery rhinorrhea and crusts in the anterior nasal cavity
are frequent characteristic findings, but are not always present.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> Other possible findings are
blepharoconjunctivitis, generalized micropapular rash and lymphadenopathy . Recalcitrant
bacterial skin infection by saprophytic organisms (Staphylococcus aureus and/or
Streptococcus &#x3B2;-haemolyticus) also occurs. It is supposed that these symptoms would
result from immunosuppressive effects of HTLV-1.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup> In 1998, La Grenade et
al., set diagnostic criteria for ID (<xref ref-type="table" rid="t02">Chart
2</xref>).</p>
      <table-wrap id="t02" orientation="portrait" position="float">
        <label>CHART 2</label>
        <caption>
          <p>Diagnostic criteria of infectious dermatitis</p>
        </caption>
        <table frame="box" rules="groups">
          <tbody>
            <tr>
              <td colspan="2" align="left" rowspan="1"><bold>MAJOR CRITERIA</bold>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">1.</td>
              <td align="left" rowspan="1" colspan="1">Eczema in two or more areas: scalp, armpits, groin, outer ear,
retroauricular region, eyelid margins, perinasal area and/or neck.</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2.</td>
              <td align="left" rowspan="1" colspan="1">Chronic rhinorrhea without other signs of rhinitis and/or
crusted lesions in nasal vestibule</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">3.</td>
              <td align="left" rowspan="1" colspan="1">Chronic recurrent dermatitis with immediate response to
antibiotic therapy but with relapse after cessation of treatment</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">4.</td>
              <td align="left" rowspan="1" colspan="1">Onset in childhood</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">5.</td>
              <td align="left" rowspan="1" colspan="1">Seropositivity for HTLV-1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
              <td align="left" rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td colspan="2" align="left" rowspan="1"><bold>MINOR CRITERIA</bold>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">1.</td>
              <td align="left" rowspan="1" colspan="1">Positive cultures for<italic> Staphylococcus aureus</italic>
and/or<italic> streptococcus</italic> &#x3B2;<italic>- hemolytic</italic> in
skin or nostrils</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2.</td>
              <td align="left" rowspan="1" colspan="1">Papulous rash</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">3.</td>
              <td align="left" rowspan="1" colspan="1">Generalized lymphadenopathy with<italic> dermatopathic lym
phadenitis</italic>&#xA0;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">4.</td>
              <td align="left" rowspan="1" colspan="1">Anemia</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">5.</td>
              <td align="left" rowspan="1" colspan="1">Increased erythrocyte sedimentation rate</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">6.</td>
              <td align="left" rowspan="1" colspan="1">Hypergammaglobulinemia IgD and IgE</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">7.</td>
              <td align="left" rowspan="1" colspan="1">Increased CD4 and CD8 and CD4/CD8 ratio</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="TFN02">
            <p>The presence of items 1, 2 and 5 among major criteria, and at least two areas
of the first item are mandatory to meet criterion 1.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>The recommended treatment ID is long-term systemic antibiotic-therapy until puberty,
when the severity of the bacterial infection is expected to subside. Oral
trimethoprim-sulfamethoxazole is the treatment of choice for its effectiveness, low cost
and availability.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>Histology shows changes observed in other eczemas. It shows hyperkeratosis and/or
parakeratosis, with crusts and acanthosis of varying degrees. We observe a mild
infiltration of T lymphocytes in the dermis. Immunohistochemistry reveals the
predominance of CD8 + cells in the skin and small percentage of cells with cytotoxic
granules, suggesting that most CD8 + lymphocytes are not activated.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup>
Diagnosis depends on the confirmation of serum-reactivity by Western blot analysis or
polymerase chain reaction (PCR).<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>Epidemiological data suggest that ID in children can be a precursor to the development
of ATLL or HAM/TSP in adolescence and adulthood.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup>Primo et al, identified a
30% occurrence of HAM/TSP among patients previously diagnosed with ID. To date, only 6
cases of HAM/TSP associated with ID have been described, indicating a greater
association between these two conditions than previously thought. The association
between ID and HAM/TSP in childhood and adolescence has been reported in less than 10
cases in the literature.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>The overactive immune response seen in ID and HAM/TSP indicates that both diseases may
have a similar pathogenesis. The rapid progression of ID to HAM/TSP may be the result of
a vigorous humoral anti-HTLV-1 response. The increased levels of antibodies seen in ID,
together with the already defined role of humoral immunity in the development HAM/TSP
supports this theory.</p>
      <p>ID may be the initial manifestation of HTLV-1 infection. Therefore, it can serve as an
early clinical marker for HTLV-1 infection and an indicator of increased risk for the
development of other HTLV-1-associated diseases. Therefore, these patients should be
followed up for a long time.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>It is recommended to perform the serology for HTLV-1 detection in patients with severe
and resistant eczemas. Dermatologists should be familiar with these changes, since their
recognition may lead to early diagnosis and adoption of important measures at the
individual, family and collective levels.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup> HTLV-I infection and
associated diseases are remarkable for their severity and emerge as a serious public
health problem.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Steglich RB, Tonoli RE, Souza PRM, Pinto GM,
Riesgo RS. HTLV-1-associated infective dermatitis and probable HTLV-1-associated
myelopathy in an adolescent female. An Bras Dermatol. 2015;90 (3 Suppl 1): S55-8.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Study conducted at the Santa Casa de Miseric&#xF3;rdia de Porto Alegre - Porto Alegre
(RS), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bittencourt</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Infective Dermatitis Associated to HTLV-I - A Review</article-title>
          <source>An Bras Dermatol</source>
          <year>2001</year>
          <volume>76</volume>
          <fpage>723</fpage>
          <lpage>732</lpage>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ara&#xFA;jo</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alves</surname>
              <given-names>DU</given-names>
            </name>
            <name>
              <surname>Carneiro-Proietti</surname>
              <given-names>ABF</given-names>
            </name>
            <name>
              <surname>Proietti</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Guedes</surname>
              <given-names>ACM</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous manifestations in human T-cell lymphotropic v&#xED;rus type 1
infection</article-title>
          <source>An Bras Dermatol</source>
          <year>2008</year>
          <volume>83</volume>
          <fpage>393</fpage>
          <lpage>407</lpage>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carneiro-Proietti</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Ribas</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Catalan-Soares</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Brito-Melo</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Martins-Filho</surname>
              <given-names>OA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Infec&#xE7;&#xE3;o e doen&#xE7;a pelos v&#xED;rus linfotr&#xF3;picos humanos de c&#xE9;lulas T
(HTLV-I/II) no Brasil</article-title>
          <source>Rev Soc Bras Med Trop</source>
          <year>2002</year>
          <volume>35</volume>
          <fpage>499</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="pmid">12621671</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Human T-lymphotrophic virus type 1eassociated infective dermatitis: A
comprehensive review</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2011</year>
          <volume>64</volume>
          <fpage>152</fpage>
          <lpage>160</lpage>
          <pub-id pub-id-type="pmid">20691499</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>FLN</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>FWM</given-names>
            </name>
          </person-group>
          <article-title>Epidemiologia, fisiopatogenia e diagn&#xF3;stico laboratorial da infec&#xE7;&#xE3;o
pelo HTLV-I</article-title>
          <source>J Bras Patol Med Lab</source>
          <year>2005</year>
          <volume>41</volume>
          <fpage>105</fpage>
          <lpage>116</lpage>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kendall</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Gonz&#xE1;lez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Espinoza</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tipismana</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Verdonck</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Early Neurologic Abnormalities Associated with Human T-Cell
Lymphotropic Virus Type 1 Infection in a Cohort of Peruvian
Children</article-title>
          <source>J Pediatr</source>
          <year>2009</year>
          <volume>155</volume>
          <fpage>700</fpage>
          <lpage>706</lpage>
          <pub-id pub-id-type="pmid">19628219</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manns</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hisada</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>La Grenade</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Human T-lymphotropic virus type I infection</article-title>
          <source>Lancet</source>
          <year>1999</year>
          <volume>353</volume>
          <fpage>1951</fpage>
          <lpage>1958</lpage>
          <pub-id pub-id-type="pmid">10371587</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Oliveira</surname>
              <given-names>M de F</given-names>
            </name>
            <name>
              <surname>Vieira</surname>
              <given-names>Md</given-names>
            </name>
            <name>
              <surname>Primo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Siqueira</surname>
              <given-names>IC</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Farr&#xE9;</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Flower cells in patients with infective dermatitis associated with
HTLV-1</article-title>
          <source>J Clin Virol</source>
          <year>2010</year>
          <volume>48</volume>
          <fpage>288</fpage>
          <lpage>290</lpage>
          <pub-id pub-id-type="pmid">20541459</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Tschachler</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <chapter-title>Human Retroviral Disease: Human T-Lymphotropic Viruses</chapter-title>
          <person-group person-group-type="author">
            <name>
              <surname>Wolff</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Goldsmith</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Katz</surname>
              <given-names>SI</given-names>
            </name>
            <name>
              <surname>Gilchrest</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Paller</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Leffell</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <source>Fitzpatrick's Dermatology in General Medicine</source>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>McGraw-Hill</publisher-name>
          <year>2008</year>
          <fpage>1923</fpage>
          <lpage>1927</lpage>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Goldman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ausiello</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <source>Cecil: Tratado de Medicina Interna</source>
          <edition>22 ed</edition>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Elsevier</publisher-name>
          <year>2005</year>
          <fpage>2336</fpage>
          <lpage>2341</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
